Zobrazeno 1 - 10
of 36
pro vyhledávání: ''
Autor:
Hélène Labussière-Wallet, Stephanie Nguyen-Quoc, Amandine Luc, Thomas Remen, Jacques-Olivier Bay, Edouard Forcade, Rémi Dulery, Marie-Thérèse Rubio, Célestine Simand, Micha Srour, Maud d'Aveni, Ambroise Marçais, Sabine Furst, Arnaud Campidelli, Patrice Ceballos, Etienne Daguindau, Marie Robin, Pascal Turlure
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
Clinical Lymphoma, Myeloma & Leukemia, Elsevier, In press, ⟨10.1016/j.clml.2021.07.027⟩
Clinical Lymphoma, Myeloma & Leukemia, Elsevier, In press, ⟨10.1016/j.clml.2021.07.027⟩
International audience; BackgroundAllogeneic hematopoietic stem-cell transplantation (allo-HSCT) remains the best curative option for high-risk myelodysplastic syndrome . We retrospectively compared patient outcomes after allo-HSCT according to the i
Autor:
William R. Drobyski, Nirav N. Shah, Walter L. Longo, Timothy S. Fenske, Bicky Thapa, Anita D'Souza, Sergey Tarima, Muhammad Bilal Abid, Saurabh Chhabra, Huaying Dong, Parameswaran Hari, Binod Dhakal, Mehdi Hamadani
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e775-e781
Engraftment syndrome (ES) after autologous hematopoietic cell transplantation (AHCT) in multiple myeloma (MM) encompasses a continuum of periengraftment complications characterized by noninfectious fever, rash, diarrhea, and capillary leak features.W
Autor:
Rasmus T. Hoeg, Matthew E. Tenold, Rajeev Krishnan, Mehrdad Abedi, Brian A. Jonas, Aaron S. Rosenberg, Joseph Tuscano, Benjamin N Moskoff
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e611-e618
Background FLAG ± Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin), is a salvage chemotherapy regimen for relapsed or refractory (R/R) acute myeloid leukemia (AML), with complete remission (CR) rates historically
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e423-e427
Background In Canadian adults, follicular lymphoma (FL) is the most common subtype of non-Hodgkin lymphomas. Approximately 20% of patients with FL experience progression of disease within 2 years of first-line chemoimmunotherapy. Those patients have
Autor:
Monia Sigle, Siddhartha Ganguly, Shebli Atrash, Zahra Mahmoudjafari, Ghulam Rehman Mohyuddin, Joseph P. McGuirk, Al-Ola Abdallah, Hameem I Kawsar, Leyla Shune
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e212-e219
Background The number of therapeutic options for patients with relapsed/refractory multiple myeloma (RRMM) has increased significantly. Our institute treated a series of patients with RRMM using DPd (daratumumab, pomalidomide, dexamethasone) as salva
Autor:
Jörn C. Albring, Christoph Schliemann, Matthias Stelljes, Christoph Groth, Patrick Stelmach, Christian Reicherts, Wolfgang E. Berdel, Georg Lenz, Klaus Wethmar, Jan-Henrik Mikesch, Daniela V. Wenge
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e724-e733
Background Blinatumomab and inotuzumab ozogamicin are now widely used to treat relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Patients and Methods We have reported the clinical course of 34 adult patients with r/r B-ALL recei
Autor:
Moussab Damlaj, Mohammad Snnallah, Ayman Alhejazi, Bader Alahmari, Mohsen Alzahrani, Razan Bashir, Hind Salama, Ahmed Alaskar, Inaam Shehab Eddine
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:690-696
Background Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with cytarabine and methotrexate (hyper-CVAD) is a commonly used regimen in adults with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (
Autor:
Raewyn Broady, Michael J. Barnett, Stephen H. Nantel, Cynthia L. Toze, Kevin W. Song, Heather J. Sutherland, Wasithep Limvorapitak, Shruthi Kodad, Maryse M. Power, Alina S. Gerrie, Yasser Abou Mourad, David Sanford, Thomas J. Nevill, Donna E. Hogge, Donna L. Forrest, Jennifer White, Sujaatha Narayanan
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:784-790
Background Autologous stem cell transplant (ASCT) is the preferred consolidation strategy to treat eligible patients with multiple myeloma (MM) and related plasma cell dyscrasias. Given the increasing volume of patients and longer wait time, outpatie
Autor:
Simon J. Harrison, Erica M. Wood, Cameron Wellard, Tracy King, Elizabeth Moore, Zoe McQuilten, Noemi Horvath, Hilary Blacklock, Krystal Bergin, Brian Rosengarten, Hang Quach, Andrew Spencer, Peter Mollee, Patricia Walker, P. Joy Ho, Christopher M. Reid, Bradley Augustson
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e415-e424
Background Renal impairment (RI) is a common complication of multiple myeloma (MM) and remains a poor prognostic factor despite improved survival with newer therapies. Patients and Methods We evaluated baseline characteristics, treatment, and outcome
Autor:
Michal Kolář, Petr Cetkovský, Cyril Šálek, Marketa Markova, Milena Vrana, L. Nováková, Veronika Valkova, Robert Pytlik, Petr Lesný, Jan Vydra, Barbora Čemusová, Antonin Vitek, Petr Soukup
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:365-371
Introduction Survival rate of patients with chemorefractory acute myeloid leukemia (AML) or myelodysplastic syndrome with excess blasts (MDS-EB) is poor. Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy in